Drugs / Tritanrix-HepB/Hib
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00829010 Background | Feb 2009 → Jun 2011 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tritanrix-HepB/Hib | “3 primary vaccine doses (at 6, 10 \& 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib” NCT00829010 ↗ |
| Modality | Vaccine | “3 primary vaccine doses (at 6, 10 \& 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib” NCT00829010 ↗ |
| Route | Intramuscular | “the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh” NCT00829010 ↗ |